Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;42(7):1968-1974.
doi: 10.1007/s00261-017-1086-7.

The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer

Stephanie Nougaret  1   2 , Nicola Robertson  3 , Jennifer Golia Pernicka  3 , Nicolas Molinari  4 , Andreas M Hötker  3 , Behfar Ehdaie  5 , Evis Sala  3 , Hedvig Hricak  3 , Hebert Alberto Vargas  3
Affiliations

The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer

Stephanie Nougaret et al. Abdom Radiol (NY). 2017 Jul.

Abstract

Purpose: To assess the performance of the updated Prostate Imaging Reporting and Data System (PI-RADSv2) and the apparent diffusion coefficient (ADC) for predicting confirmatory biopsy results in patients considered for active surveillance of prostate cancer (PCA).

Methods: IRB-approved, retrospective study of 371 consecutive men with clinically low-risk PCA (initial biopsy Gleason score ≤6, prostate-specific antigen <10 ng/ml, clinical stage ≤T2a) who underwent 3T-prostate MRI before confirmatory biopsy. Two independent radiologists recorded the PI-RADSv2 scores and measured the corresponding ADC values in each patient. A composite score was generated to assess the performance of combining PI-RADSv2 + ADC.

Results: PCA was upgraded on confirmatory biopsy in 107/371 (29%) patients. Inter-reader agreement was substantial (PI-RADSv2: k = 0.73; 95% CI [0.66-0.80]; ADC: r = 0.74; 95% CI [0.69-0.79]). Accuracies, sensitivities, specificities, positive predicted value and negative predicted value of PI-RADSv2 were 85, 89, 83, 68, 95 and 78, 82, 76, 58, 91% for ADC. PI-RADSv2 accuracy was significantly higher than that of ADC for predicting biopsy upgrade (p = 0.014). The combined PI-RADSv2 + ADC composite score did not perform better than PI-RADSv2 alone. Obviating biopsy in patients with PI-RADSv2 score ≤3 would have missed Gleason Score upgrade in 12/232 (5%) of patients.

Conclusion: PI-RADSv2 was superior to ADC measurements for predicting PCA upgrading on confirmatory biopsy.

Keywords: Biopsy; Cancer; Confirmatory; PI-RADSv2; Prostate.

PubMed Disclaimer

Conflict of interest statement

None of the authors declare a conflict of interest.

Figures

Figure 1
Figure 1
Study design
Figure 2
Figure 2
Patients characteristics
Figure 3
Figure 3
T2 weighted image (A, D), ADC map (B, E) and fused T2 weighted image and ADC map (C, F) demonstrate a PI-RADSv2 5 lesion (white arrow) within the right transition zone (A, B, C) and left mid gland peripheral zone (D, E, F). T2 weighted image (G), ADC map (H) and fused T2 weighted image and ADC map (I) demonstrate a vague T2 (white arrow, G) non measurable lesion with mild diffusion restriction (white arrow, H, I) classified as PI-RADSv2 2 lesion. White circle on C, F and I demonstrate ADC ROI.
See this image and copyright information in PMC

References

    1. Adamy A, Yee DS, Matsushita K, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011;185:477–482. - PMC - PubMed
    1. Wong LM, Alibhai SM, Trottier G, et al. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. Eur Urol. 2014;66:406–413. - PubMed
    1. Wong LM, Ferrara S, Alibhai SM, et al. Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:69–74. - PubMed
    1. Dall’Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976–983. - PubMed
    1. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011;29:2795–2800. - PubMed

Publication types